What question did this study set out to answer?

To evaluate the effectiveness of different PET/CT tracers for staging intrahepatic cholangiocarcinoma.

February 5, 2026

Optimizing Intrahepatic Cholangiocarcinoma Staging

Key Points

To evaluate the effectiveness of different PET/CT tracers for staging intrahepatic cholangiocarcinoma.
Case evaluation of a patient with intrahepatic cholangiocarcinoma
Conducted PET/CT scans using [18F]FDG, [68Ga]Ga-Trivehexin, and [68Ga]Ga-FAPI-04
Analyzed tracer uptake in primary lesions and metastatic lymph nodes.
[68Ga]Ga-Trivehexin effectively visualizes metastatic cervical and abdominal lymph nodes
[18F]FDG shows limited visibility for certain metastatic sites
[68Ga]Ga-FAPI-04 outperforms [18F]FDG in delineating metastasis.

Abstract

Herein, we present a case of a patient with intrahepatic cholangiocarcinoma (ICC) who underwent 18 FFDG, 68 GaGa-Trivehexin, and 68 GaGa-FAPI-04 PET/CT scans for initial staging. The primary liver lesion demonstrates progressively increased uptake across all 3 tracers, whereas metastatic cervical lymph nodes are visualized with 68 GaGa-FAPI-04 PET/CT and 68 GaGa-Trivehexin but not with 18 FFDG; importantly, 68 GaGa-FAPI-04 PET/CT, in addition, delineates metastatic abdominal lymph nodes. This case highlights that 68 GaGa-Trivehexin PET/CT may serve as an alternative to 18 FFDG PET/CT, warranting reevaluation of FDG limitations, while FAPI remains a strong competitor to both.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Zorba et al. (Tue,) studied this question.

synapsesocial.com/papers/6984348bf1d9ada3c1fb2d0b https://doi.org/https://doi.org/10.1097/rlu.0000000000006310

AI에게 질문

Bookmark

View Full Paper